Amicus Therapeutics FOLD reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM.
Here's what investors need to know about the announcement.
Earnings
Amicus Therapeutics beat estimated earnings by 36.84%, reporting an EPS of $-0.12 versus an estimate of $-0.19.
Revenue was up $2.15 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.01 which was followed by a 11.33% increase in the share price the next day.
Here's a look at Amicus Therapeutics's past performance:
Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
---|---|---|---|---|
EPS Estimate | -0.22 | -0.25 | -0.16 | -0.18 |
EPS Actual | -0.21 | -0.30 | -0.29 | -0.19 |
Revenue Estimate | 85.89M | 77.13M | 83.28M | 80.11M |
Revenue Actual | 80.73M | 78.72M | 82.15M | 79.55M |
To track all earnings releases for Amicus Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.